Massmutual Trust Co. FSB ADV Buys 29 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Massmutual Trust Co. FSB ADV increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 361 shares of the company’s stock after purchasing an additional 29 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in IDEXX Laboratories were worth $182,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Nordea Investment Management AB boosted its stake in shares of IDEXX Laboratories by 15.5% in the 1st quarter. Nordea Investment Management AB now owns 13,719 shares of the company’s stock worth $7,447,000 after buying an additional 1,839 shares during the last quarter. Manning & Napier Advisors LLC purchased a new position in IDEXX Laboratories in the second quarter worth about $20,418,000. Brevan Howard Capital Management LP bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at about $3,183,000. First Hawaiian Bank purchased a new stake in shares of IDEXX Laboratories during the 1st quarter valued at about $982,000. Finally, Meyer Handelman Co. bought a new position in shares of IDEXX Laboratories in the 1st quarter worth approximately $2,155,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on IDXX shares. Piper Sandler dropped their price objective on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a report on Wednesday, August 14th. BTIG Research assumed coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price objective for the company. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Finally, Stifel Nicolaus lowered their target price on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research report on Monday, June 24th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $582.25.

IDEXX Laboratories Stock Down 1.2 %

Shares of IDXX stock opened at $477.67 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The company’s fifty day moving average price is $487.95 and its 200-day moving average price is $495.89. The company has a market capitalization of $39.45 billion, a price-to-earnings ratio of 46.24, a PEG ratio of 4.32 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the business earned $2.67 earnings per share. IDEXX Laboratories’s revenue was up 6.4% compared to the same quarter last year. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 10.45 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.